Skip to main content

Table 4 Relative hazards of infection for anakinra versus methotrexate and anakinra versus methotrexate with systemic juvenile idiopathic arthritis

From: The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis

Exposure Comparator Unadjusted relative hazard (95 % CI) Adjusteda relative hazard (95 % CI)
Anakinra MTX 5.69 (3.30–9.81) 3.53 (1.83–6.82)
 Hospitalized infection during baseline No infection during baseline   4.81 (1.94–11.9)
 Nonprimary hospitalized or outpatient infection during baseline No infection during baseline   1.76 (0.99–3.16)
 High-dose oral GC (≥10 mg/day) No oral GC use during baseline   2.79 (1.35–5.78)
 Low-dose oral GC (<10 mg/day) No oral GC use during baseline   1.06 (0.54–2.08)
Anakinra MTX with SJIA 3.07 (0.93–10.2) 2.69 (0.82–8.82)
 Hospitalized infection during baseline No infection during baseline   3.10 (0.74–12.9)
 Nonprimary hospitalized or outpatient infection during baseline No infection during baseline   1.76 (0.66–4.72)
 High-dose oral GC (≥10 mg/day) No oral GC use during baseline   2.05 (0.57–7.30)
 Low-dose oral GC (<10 mg/day) No oral GC use during baseline   1.59 (0.41–6.09)
  1. Abbreviations: MTX Methotrexate, SJIA Systemic juvenile idiopathic arthritis, mg Milligrams of prednisone equivalents, GC Glucocorticoid
  2. aMultivariable model included the following variables: new anakinra use, age, sex, asthma, baseline oral GC dose, infection during baseline period, cyclosporine use (time-varying).
\